CD36

New Clinical Trials Report on Glioblastoma Pipeline Insights - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 10, 2023
Pharmaceutical, Health, Oncology, Human, CD47, Central nervous system, Therapy, GBM, Neoplasm, Salinosporamide A, Clinical trial, Prognosis, PKC, Brain, Bristol Myers Squibb, CNS, II, PI3K, AKT, Glomus tumor, Get Behind Me Satan, CD36, News, DRD2, Pharmaceutical industry, Medical imaging, Glioblastoma

The "Glioblastoma Pipeline Insight 2023" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glioblastoma Pipeline Insight 2023" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This report offers comprehensive insights about more than 190 companies and over 200 pipeline drugs in the Glioblastoma pipeline landscape.
  • The report presents a detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and discovery.
  • It covers clinical trial details, pharmacological action, agreements and collaborations, and the latest news and press releases related to Glioblastoma.

Vigeo Therapeutics will present New Clinical and Immune Profiling Data from Ph I/II Expansion study in GBM Patients in ASCO Poster Oral Session

Retrieved on: 
Friday, June 2, 2023
CD47, PD, GBM, Survival, American Society of Clinical Oncology, Glioblastoma, Trial of the century, ASCO, MDSC, PD-L1, Patient, TME, Decompression (diving), CR, CTL, CD36, Therapy, Tumor microenvironment, Phenotype, Society, SD, Pharmaceutical industry, Cleveland Clinic

VT1021 is a first-in-class compound that, by binding to MDSCs, induces the expression of thrombospondin-1 (Tsp-1) in the tumor microenvironment (TME).

Key Points: 
  • VT1021 is a first-in-class compound that, by binding to MDSCs, induces the expression of thrombospondin-1 (Tsp-1) in the tumor microenvironment (TME).
  • In a phase I/II clinical study in solid tumors (NCT03364400) VT1021 demonstrated promising single-agent clinical activity against recurrent glioblastoma.
  • Historically, rGBM patients have a response rate of less than 5% and a median progression free survival of 48 days.
  • Title: Immune profiling in patients with glioblastoma treated with VT1021 in a phase I/II expansion study.

Vigeo Therapeutics New Immune Profiling and Biomarker Data Ph I/II Expansion study in GBM Patients

Retrieved on: 
Thursday, May 25, 2023
CD47, MOA, PD, GBM, Survival, American Society of Clinical Oncology, Glioblastoma, Trial of the century, ASCO, MDSC, PD-L1, Patient, TME, Decompression (diving), CR, CTL, CD36, Therapy, Tumor microenvironment, Phenotype, Society, SD, Pharmaceutical industry

VT1021 is a first-in-class compound that, by binding to MDSCs, induces the expression of thrombospondin-1 (Tsp-1) in the tumor microenvironment (TME).

Key Points: 
  • VT1021 is a first-in-class compound that, by binding to MDSCs, induces the expression of thrombospondin-1 (Tsp-1) in the tumor microenvironment (TME).
  • In a phase I/II clinical study in solid tumors (NCT03364400), VT1021 demonstrated promising single-agent clinical activity against recurrent glioblastoma.
  • Vigeo is already studying the therapeutic effect of VT1021 in both newly diagnosed and recurrent GBM in an ongoing phase II/III clinical study (NCT03970447).
  • Title: Immune profiling in patients with glioblastoma treated with VT1021 in a phase I/II expansion study.

MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

Retrieved on: 
Tuesday, August 9, 2022
FDA, Intellectual property, U.S. Securities and Exchange Commission, Cardiovascular disease, CCR2, Chronic kidney disease, CD36, Nasdaq, Hepatocyte, Risk, Tokyo Stock Exchange, Gene, Inflammation, Arachidonic acid, International Diabetes Federation, Metabolic syndrome, MS, IPF, GLOBE, Failure, Hypercholesterolemia, Private Securities Litigation Reform Act, IDF, Non-alcoholic fatty liver disease, MCP-1, Code, T2DM, Incidence, Amyotrophic lateral sclerosis, Prevalence, Congress, Security (finance), Research, LOXL2, Hypertriglyceridemia, Form 8-K, Patient, Fibrosis, Type 2 diabetes, NAFLD, PDE, Form 10-K, DCM, Neurodegeneration, NASDAQ, Idiopathic pulmonary fibrosis, Glioblastoma, Dyslipidemia, ABCG1, MD, Annual report, ALS, Multiple sclerosis, RNA transfection, Malignancy, Pharmaceutical industry

This subgroup analysis was conducted based on in-vitro research findings that MN-001 down regulated CD36 mRNA and upregulated ABCG1 mRNA.

Key Points: 
  • This subgroup analysis was conducted based on in-vitro research findings that MN-001 down regulated CD36 mRNA and upregulated ABCG1 mRNA.
  • NAFLD is considered the hepatic manifestation of metabolic syndrome; studies have reported that 50% of patients with metabolic syndrome also have NAFLD.
  • The presence of dyslipidemia (hypercholesterolemia, hypertriglyceridemia, or both) is reported in 20 - 80% of NAFLD cases.
  • Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof.

Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial

Retrieved on: 
Wednesday, July 6, 2022
Oncology, Health, Health Technology, Clinical Trials, Pharmaceutical, Biotechnology, Patient, MPO, Selection Committee, National Brain Tumor Society, Principal investigator, Myostatin, Immune system, EMA, Homeostasis, Neoplasm, CTL, Stanford University, CD36, Therapy, NDA, Apoptosis, Tic disorder, Department, FDA, Migraine, Endothelium, Amyotrophic lateral sclerosis, Huntsman Cancer Institute, Pancreatic cancer, Global Coalition Against Pneumonia, NYSE, DRS, Twitter, GBM, LinkedIn, University of Utah, Sponsor, Health, Degenerative disease, Survival rate, Multimedia, Coalition, Spinocerebellar ataxia, Disease, National Foundation for Cancer Research, University Hospital of Zürich, Teaching hospital, EAAT2, Cancer, Principal, University, CD47, Henry Ford, Tumor microenvironment, Brain, Physician, BLA, United Nations Foundation, Pharmaceutical industry, Medical device, Glioblastoma

Global Coalition for Adaptive Research (LARKSPUR, CA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), and Vigeo Therapeutics -- The Global Coalition for Adaptive Research (GCAR) in collaboration with Biohaven and Vigeo Therapeutics, today announced the activation of Biohaven's troriluzole and Vigeo's VT1021 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment).

Key Points: 
  • Global Coalition for Adaptive Research (LARKSPUR, CA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), and Vigeo Therapeutics -- The Global Coalition for Adaptive Research (GCAR) in collaboration with Biohaven and Vigeo Therapeutics, today announced the activation of Biohaven's troriluzole and Vigeo's VT1021 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment).
  • View the full release here: https://www.businesswire.com/news/home/20220706005204/en/
    Biohaven's troriluzole and Vigeo's VT1021 are entering the GBM AGILE trial, which initially opened in July 2019 and has screened over 1200 patients to date.
  • We are excited to include troriluzole and VT1021 in GBM AGILE.
  • We are enthusiastic to be the first site to activate troriluzole and VT1021 in the GBM AGILE study.

Global Coalition for Adaptive Research Announces Key Updates on GBM AGILE Phase 2-3 Adaptive Platform Trial for Patients With Glioblastoma

Retrieved on: 
Tuesday, January 18, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, NDA, Patient, Coalition, CD47, CTL, Health, MGMT, University, Apoptosis, National Brain Tumor Society, Huntsman Cancer Institute, Endothelium, BLA, University Hospital of Zürich, GBM, Brain, NYSE, CEO, United Nations Foundation, Disease, Department, Glioblastoma, IND, Cancer, Global Coalition Against Pneumonia, Stanford University, Industry, Homeostasis, Tumor microenvironment, Drug development, National Foundation for Cancer Research, CD36, Immune system, Neoplasm, EAAT2, FDA, Principal, Teaching hospital, Physician, University of Utah, Medical imaging, Pharmaceutical industry, Tourism, Medical device

Global Coalition for Adaptive Research (GCAR) today announced an update on the progress of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment - NCT03970447).

Key Points: 
  • Global Coalition for Adaptive Research (GCAR) today announced an update on the progress of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment - NCT03970447).
  • GBM AGILE is a revolutionary patient-centered, adaptive platform trial for registration that tests multiple therapies for patients with newly-diagnosed and recurrent glioblastoma (GBM) the deadliest form of brain cancer.
  • GBM AGILE is an international, innovative platform trial designed to more rapidly identify and confirm effective therapies for patients with glioblastoma through response adaptive randomization and a seamless phase 2/3 design.
  • GCAR is the sponsor of GBM AGILE, an adaptive platform trial for patients with GBM the most common and deadliest of malignant primary brain tumors.

Vigeo Therapeutics Announces New Phase 1/2 Data from its Expansion Study of VT1021 at the Society of NeuroOncology's 2021 Annual Meeting

Retrieved on: 
Tuesday, November 16, 2021
Safety, M2, Brain, SNO, DCR, Therapy, Glioblastoma, Mass flow (life sciences), GBM, TME, Society, CD47, Tumor microenvironment, Annual general meeting, Phenotype, SD, Neuro-oncology, Pancreatic cancer, Patient, CD36, MDSC, Pharmaceutical industry, Medical imaging

The data is being presented in a poster session at the Society for NeuroOncology's (SNO) 2021 Annual Meeting, taking place from November 18-21, 2021 in Boston.

Key Points: 
  • The data is being presented in a poster session at the Society for NeuroOncology's (SNO) 2021 Annual Meeting, taking place from November 18-21, 2021 in Boston.
  • VT1021 is a first-in-class compound that, by binding to MDSCs, induces the expression of thrombospondin-1 (Tsp-1) in the tumor microenvironment (TME.
  • "In the expansion study, VT1021 demonstrated noteworthy single-agent clinical activity in rGBM, particularly in subjects with high expression levels of CD36 and CD47.
  • Details for the SNO 2021 presentation are as follows:
    Title:Clinical efficacy and biomarker assessment of VT1021, a CD36/CD47 dual-targeting agent, in recurrent glioblastoma

MediciNova Announces Abstract regarding the Mechanism by which MN-001 (tipelukast) Alters Triglyceride Metabolism Accepted for Presentation at the 19th International Symposium on Atherosclerosis (ISA2021)

Retrieved on: 
Thursday, October 21, 2021
Fibrosis, Form 8-K, Idiopathic pulmonary fibrosis, Kyoto International Conference Center, TG, Fatty liver disease, Gene, Annual report, Hypertriglyceridemia, Neurodegeneration, Failure, International Symposium on Reliable Distributed Systems, Triglyceride, NAFLD, Code, Security (finance), Substance dependence, MCP-1, U.S. Securities and Exchange Commission, NASDAQ, Arachidonic acid, FDA, Narration, Patient, Private Securities Litigation Reform Act, Multiple sclerosis, Â, MS, Risk, Tokyo Stock Exchange, Conference, CD36, Glioblastoma, National Institute of General Medical Sciences, Inflammation, Amyotrophic lateral sclerosis, CCR2, Form 10-K, IPF, Serum, DCM, NASH, Intellectual property, GLOBE, Associate, LOXL2, ALS, Nasdaq, PDE, Hepatocyte, Pharmaceutical industry

Dr. Oguras e-presentation with narration will be accessible on the ISA2021 website from October 25 to November 30, 2021.

Key Points: 
  • Dr. Oguras e-presentation with narration will be accessible on the ISA2021 website from October 25 to November 30, 2021.
  • Ph.D, MPH., Chief Medical Officer, MediciNova, Inc., commented, It has been observed that MN-001 treatment reduces serum TG levels in multiple previous clinical trials.
  • We are very pleased that Dr. Ogura will present new findings regarding the mechanism by which MN-001 alters intracellular triglyceride metabolism.
  • Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof.

Vigeo Therapeutics to Present New Phase 1/2 VT1021 Data from its Pancreatic Cancer Expansion Study at the Society for Immunotherapy of Cancer's 2021 Annual Meeting

Retrieved on: 
Friday, October 1, 2021
Therapy, Glioblastoma, Cancer, Neoplasm, Cancer immunotherapy, CD47, Pancreatic cancer, CD36, AM, Patient, Annual general meeting, Development, Biomarker, Immune system, Immunotherapy, Apoptosis, Date, Society for Immunotherapy of Cancer, M1, Doctor of Philosophy, Tumor microenvironment, Time, SITC, Society, Pharmaceutical industry, Medical imaging, Book

The company will present data fromthe pancreatic cancer expansion cohort with single-agent VT1021 which demonstrated tumor reduction in multiple subjects with measurable disease.

Key Points: 
  • The company will present data fromthe pancreatic cancer expansion cohort with single-agent VT1021 which demonstrated tumor reduction in multiple subjects with measurable disease.
  • The second poster demonstrates the utility of Tsp-1 as a pharmacodynamic biomarker and its correlation with clinical response.
  • Vigeo is developing VT1021 as a therapeutic agent across a range of cancers, with a current focus on solid tumors.
  • Based in Cambridge, MA, Vigeo Therapeutics is a clinical-stage immuno-oncology company pioneering novel cancer therapies.

Vigeo Therapeutics Provides Clinical Update for Lead Asset VT1021 and Welcomes New Chief Executive Officer

Retrieved on: 
Tuesday, September 21, 2021
Biotechnology, Therapy, Glioblastoma, Neoplasm, Cancer, Baxter International, Dade Behring, PI, CD47, Health, Pancreatic cancer, CD36, University, Economics, Patient, Mass flow (life sciences), Management, TME, GBM, CEO, Apoptosis, MMA, University of Massachusetts Medical School, MBA, Northwestern University, Safety, M1, Doctor of Philosophy, Tumor microenvironment, FMC Corporation, COO, BS, Pharmaceutical industry, Vaccine

While the expansion study has concluded, these subjects will continue to receive VT1021 in an open label extension study.

Key Points: 
  • While the expansion study has concluded, these subjects will continue to receive VT1021 in an open label extension study.
  • Prior to joining Vigeo as CEO, Mr. Mahoney served as a member of the Vigeo Board of Directors since 2015.
  • Vigeo is developing VT1021 as a therapeutic agent across a range of cancers, with a current focus on solid tumors.
  • Based in Cambridge, MA, Vigeo Therapeutics is a clinical-stage immuno-oncology company pioneering novel cancer therapies.